The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: A review by cancer site

Histology and Histopathology

Volumn 30, Issue 5, 2015, Pages 503-521

  Orzol, Paulina ^a   Holcakova, Jitka ^a   Nekulova, Marta ^a   Nenutil, Rudolf ^a   Vojtesek, Borivoj ^a   Coates, Philip J ^b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; P53; P63; P73; Tumorigenesis

Indexed keywords

DNA BINDING PROTEIN; NUCLEAR PROTEIN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

BIOLOGICAL MODEL; CARCINOGENESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; NEOPLASM; ONCOGENE; PHYSIOLOGY; POINT MUTATION; TUMOR SUPPRESSOR GENE;

BIOMARKERS, TUMOR; CARCINOGENESIS; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MODELS, GENETIC; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENES; POINT MUTATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84929762237     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-30.503     Document Type: Review

References (233)

1. Adithi M., Nalini V., Kandalam M. and Krishnakumar S. (2008). Expression of p63 and p73 in retinoblastoma: a clinicopathological correlation study. Exp. Eye Res. 87, 312-318.
2. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M. B., Guzzardo V., Parenti A.R., Rosato A., Bicciato S., Balmain A. and Piccolo S. (2009). A Mutantp53/ Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98.
3. Agostini M., Tucci P., Chen H., Knight R.A., Bano D., Nicotera P., McKeon F. and Melino G. (2010). p73 regulates maintenance of neural stem cell. Biochem. Biophys. Res. Commun. 403, 13-17.
4. Agostini M., Tucci P., Killick R., Candi E., Sayan B.S., Rivetti di Val Cervo P., Nicotera P., McKeon F., Knight R.A., Mak T.W. and Melino G. (2011). Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc. Natl. Acad. Sci. USA 108, 21093-21098.
5. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., Zhang N., El-Naggar A.K., Jasser S.A., Weinstein J.N., Trevino L., Drummond J.A., Muzny D.M., Wu Y., Wood L.D., Hruban R. H., Westra W.H., Koch W.M., Califano J.A., Gibbs R.A., Sidransky D., Vogelstein B., Velculescu V.E., Papadopoulos N., Wheeler D.A., Kinzler K.W. and Myers J.N. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157.
6. Alexandrova E.M. and Moll U.M. (2012). Role of p53 family members p73 and p63 in human hematological malignancies. Leuk Lymphoma 53, 2116-2129.
7. Ali T.Z. and Epstein J.I. (2007). Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am. J. Surg. Pathol. 31, 697-705.
8. Alla V., Kowtharapu B.S., Engelmann D., Emmrich S., Schmitz U., Steder M. and Putzer B.M. (2012). E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11, 3067-3078.
9. Alomari A.K., Glusac E.J. and McNiff J.M. (2014). p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. J. Cutan. Pathol. 41, 839-845.
10. Aubry M.C., Roden A., Murphy S.J., Vasmatzis G., Johnson S.H., Harris F.R., Halling G., Knudson R.A., Ketterling R.P. and Feldman A.L. (2014). Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. Mod. Pathol. (in press).
11. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R. and Wooster R. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358.
12. Barbareschi M., Pecciarini L., Cangi M.G., Macri E., Rizzo A., Viale G. and Doglioni C. (2001). p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am. J. Surg. Pathol. 25, 1054-1060.
13. Basturk O., Khanani F., Sarkar F., Levi E., Cheng J.D. and Adsay N.V. (2005). DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod. Pathol. 18, 1193-1198.
14. Belyi V.A., Ak P., Markert E., Wang H., Hu W., Puzio-Kuter A. and Levine A.J. (2010). The origins and evolution of the p53 family of genes. Cold Spring Harb. Perspect. Biol. 2, a001198.
15. Bid H.K., Roberts R.D., Cam M., Audino A., Kurmasheva R.T., Lin J., Houghton P.J. and Cam H. (2014). DeltaNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res. 74, 320-329.
16. Bishop J.A., Teruya-Feldstein J., Westra W.H., Pelosi G., Travis W.D. and Rekhtman N. (2012). p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod. Pathol. 25, 405-415.
17. Boldrup L., Coates P.J., Gu X. and Nylander K. (2007). DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J. Pathol. 213, 384-391.
18. Boldrup L., Coates P.J., Gu X. and Nylander K. (2009). DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J. Pathol. 218, 428-436.
19. Branham M.T., Marzese D.M., Laurito S.R., Gago F.E., Orozco J.I., Tello O.M., Vargas-Roig L.M. and Roque M. (2012). Methylation profile of triple-negative breast carcinomas. Oncogenesis 1, e17.
20. Brody J.R., Costantino C.L., Potoczek M., Cozzitorto J., McCue P., Yeo C.J., Hruban R.H. and Witkiewicz A.K. (2009). Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod. Pathol. 22, 651-659.
21. Bueso-Ramos C., Xu Y., McDonnell T.J., Brisbay S., Pierce S., Kantarjian H., Rosner G. and Garcia-Manero G. (2005). Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J. Clin. Oncol. 23, 3932-3939.
22. Burington B., Yue P., Shi X., Advani R., Lau J.T., Tan J., Stinson S., Stinson J., Januario T., de Vos S., Ansell S., Forero-Torres A., Fedorowicz G., Yang T.T., Elkins K., Du C., Mohan S., Yu N., Modrusan Z., Seshagiri S., Yu S.F., Pandita A., Koeppen H., French D., Polson A.G., Offringa R., Whiting N., Ebens A. and Dornan D. (2011). CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci. Transl. Med. 3, 74ra22.
23. Butnor K.J. and Burchette J.L. (2013). p40 (DeltaNp63) and keratin 34betaE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples. Hum. Pathol. 44, 1479-1486.
24. Cancer Genome Atlas Research N. (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525.
25. Cancer Genome Atlas Research N. (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322.
26. Cao L.Y., Yin Y., Li H., Jiang Y. and Zhang H.F. (2009). Expression and clinical significance of S100A2 and p63 in esophageal carcinoma. World J. Gastroenterol. 15, 4183-4188.
27. Carastro L.M., Lin H.Y., Park H.Y., Kim D., Radlein S., Hampton K-K., Hakam A., Zachariah B., Pow-Sang J. and Park J.Y. (2014). Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer 2014, 129582.
28. Carneiro F.P., Ramalho L.N., Britto-Garcia S., Ribeiro-Silva A. and Zucoloto S. (2006). Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis. Colon Rectum 49, 588-594.
29. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P. and Romani M. (2002). Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9, 246-251.
30. Castellino R.C., De Bortoli M., Lin L.L., Skapura D.G., Rajan J.A., Adesina A.M., Perlaky L., Irwin M.S. and Kim J.Y. (2007). Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 7, 127.
31. Chakrabarti R., Wei Y., Hwang J., Hang X., Andres Blanco M., Choudhury A., Tiede B., Romano R.A., DeCoste C., Mercatali L., Ibrahim T., Amadori D., Kannan N., Eaves C.J., Sinha S. and Kang Y. (2014). DeltaNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat. Cell Biol. 16, 1004-1015.
32. Chen C.L., Ip S.M., Cheng D., Wong L.C. and Ngan H. Y. (2000). P73 gene expression in ovarian cancer tissues and cell lines. Clin. Cancer Res. 6, 3910-3915.
33. Cheung A.N., Tsun K.L., Ng K.M., Szeto E., Siu M.K., Wong E.S. and Ngan H.Y. (2010). P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytology--potential biomarkers for diagnosis and progress prediction of cervical neoplasia. Mod. Pathol. 23, 559-566.
34. Cheung K.J., Gabrielson E., Werb Z. and Ewald A.J. (2013). Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 155, 1639-1651.
35. Chi S.G., Chang S.G., Lee S.J., Lee C.H., Kim J.I. and Park J.H. (1999). Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. Cancer Res. 59, 2791-2793.
36. Chilosi M., Zamo A., Brighenti A., Malpeli G., Montagna L., Piccoli P., Pedron S., Lestani M., Inghirami G., Scarpa A., Doglioni C. and Menestrina F. (2003). Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch. 443, 175-183.
37. Choi H.R., Batsakis J.G., Zhan F., Sturgis E., Luna M.A. and El-Naggar A.K. (2002). Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum. Pathol. 33, 158-164.
38. Choi W., Shah J.B., Tran M., Svatek R., Marquis L., Lee I.L., Yu D., Adam L., Wen S., Shen Y., Dinney C., McConkey D.J. and Siefker-Radtke A. (2012). p63 expression defines a lethal subset of muscleinvasive bladder cancers. PLoS One 7, e30206.
39. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., Roth B., Cheng T., Tran M., Lee I.L., Melquist J., Bondaruk J., Majewski T., Zhang S., Pretzsch S., Baggerly K., Siefker-Radtke A., Czerniak B., Dinney C.P. and McConkey D.J. (2014). Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165.
40. Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C. and Moll U. M. (2004). Transdominant DeltaTAp73 isoforms are frequently upregulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64, 2449-2460.
41. Concin N., Hofstetter G., Berger A., Gehmacher A., Reimer D., Watrowski R., Tong D., Schuster E., Hefler L., Heim K., Mueller-Holzner E., Marth C., Moll U.M., Zeimet A.G. and Zeillinger R. (2005). Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin. Cancer Res. 11, 8372-8383.
42. Corn P.G., Kuerbitz S.J., van Noesel M.M., Esteller M., Compitello N., Baylin S.B. and Herman J.G. (1999). Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res. 59, 3352-3356.
43. Costanzo A., Pediconi N., Narcisi A., Guerrieri F., Belloni L., Fausti F., Botti E. and Levrero M. (2014). TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. FEBS Lett. 588, 2590-2599.
44. Dabir P. D., Ottosen P., Hoyer S. and Hamilton-Dutoit S. (2012). Comparative analysis of three-and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagn. Pathol. 7, 81.
45. Danilov A.V., Neupane D., Nagaraja A.S., Feofanova E.V., Humphries L.A., DiRenzo J. and Korc M. (2011). DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One 6, e26815.
46. Deyoung M.P. and Ellisen L.W. (2007). p63 and p73 in human cancer: defining the network. Oncogene 26, 5169-5183.
47. DeYoung M.P., Johannessen C.M., Leong C.O., Faquin W., Rocco J.W. and Ellisen L.W. (2006). Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 66, 9362-9368.
48. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., Pohar K., Hoos A. and Cordon-Cardo C. (2002). p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8, 494-501.
49. DiMaio M.A., Kwok S., Montgomery K.D., Lowe A.W. and Pai R.K. (2012). Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. Hum. Pathol. 43, 1799-1807.
50. Dominguez G., Silva J., Silva J.M., Garcia J.M., Larrondo F.J., Vargas J., Sanfrutos L., Provencio M., Espana P. and Bonilla F. (2001a). Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status. Genes Chromosomes Cancer 31, 99-106.
51. Dominguez G., Silva J.M., Silva J., Garcia J.M., Sanchez A., Navarro A., Gallego I., Provencio M., Espana P. and Bonilla F. (2001b). Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res. Treat. 66, 183-190.
52. Dominguez G., Garcia J.M., Pena C., Silva J., Garcia V., Martinez L., Maximiano C., Gomez M.E., Rivera J.A., Garcia-Andrade C. and Bonilla F. (2006a). DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 24, 805-815.
53. Dominguez G., Pena C., Silva J., Garcia J.M., Garcia V., Rodriguez R., Cantos B., Citores M.J., Espana P. and Bonilla F. (2006b). The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. J. Pathol. 210, 390-397.
54. Douc-Rasy S., Barrois M., Echeynne M., Kaghad M., Blanc E., Raguenez G., Goldschneider D., Terrier-Lacombe M.J., Hartmann O., Moll U., Caput D. and Benard J. (2002). DeltaN-p73alpha accumulates in human neuroblastic tumors. Am. J. Pathol. 160, 631-639.
55. Du Z., Li J., Wang L., Bian C., Wang Q., Liao L., Dou X., Bian X. and Zhao R.C. (2010). Overexpression of DeltaNp63alpha induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci. 101, 2417-2424.
56. Du C.W., Kimijima I., Otake T., Abe R., Takenoshita S. and Zhang G.J. (2011). Down-regulation of p73 correlates with high histological grade in Japanese with breast carcinomas. Chin. Med. J. (Engl) 124, 2275-2278.
57. Dugani C.B., Paquin A., Fujitani M., Kaplan D.R. and Miller F.D. (2009). p63 antagonizes p53 to promote the survival of embryonic neural precursor cells. J. Neurosci. 29, 6710-6721.
58. Dumay A., Feugeas J.P., Wittmer E., Lehmann-Che J., Bertheau P., Espie M., Plassa L.F., Cottu P., Marty M., Andre F., Sotiriou C., Pusztai L. and de The H. (2013). Distinct tumor protein p53 mutants in breast cancer subgroups. Int. J. Cancer 132, 1227-1231.
59. Fatt M.P., Cancino G.I., Miller F.D. and Kaplan D.R. (2014). p63 and p73 coordinate p53 function to determine the balance between survival, cell death, and senescence in adult neural precursor cells. Cell Death Differ. 21, 1546-1559.
60. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F. and Jacks T. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373.
61. Fomenkov A., Zangen R., Huang Y.P., Osada M., Guo Z., Fomenkov T., Trink B., Sidransky D. and Ratovitski E.A. (2004). RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 3, 1285-1295.
62. Fukushima H., Koga F., Kawakami S., Fujii Y., Yoshida S., Ratovitski E., Trink B. and Kihara K. (2009). Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Res. 69, 9263-9270.
63. Fukushima N., Satoh T., Sueoka N., Sato A., Ide M., Hisatomi T., Kuwahara N., Tomimasu R., Tsuneyoshi N., Funai N., Sano M., Tokunaga O. and Sueoka E. (2006). Clinico-pathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci. 97, 1050-1055.
64. Gailey M.P. and Bellizzi A.M. (2013). Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (DeltaNp63) in squamous cell and urothelial carcinoma. Am. J. Clin. Pathol. 140, 872-880.
65. Gao Y.B., Chen Z.L., Li J.G., Hu X.D., Shi X.J., Sun Z.M., Zhang F., Zhao Z.R., Li Z.T., Liu Z.Y., Zhao Y.D., Sun J., Zhou C.C., Yao R., Wang S.Y., Wang P., Sun N., Zhang B.H., Dong J.S., Yu Y., Luo M., Feng X.L., Shi S.S., Zhou F., Tan F.W., Qiu B., Li N., Shao K., Zhang L.J., Zhang L.J., Xue Q., Gao S.G. and He J. (2014). Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 46, 1097-1102.
66. Garcia V., Silva J., Dominguez G., Garcia J.M., Pena C., Rodriguez R., Provencio M., Espana P. and Bonilla F. (2004). Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. Mutat. Res. 554, 215-221.
67. Garcia-Manero G., Bueso-Ramos C., Daniel J., Williamson J., Kantarjian H.M. and Issa J.P. (2002a). DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin. Cancer Res. 8, 1897-1903.
68. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantarjian H.M. and Issa J.P. (2002b). DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8, 2217-2224.
69. Ghioni P., Bolognese F., Duijf P.H., Van Bokhoven H., Mantovani R. and Guerrini L. (2002). Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol. Cell Biol. 22, 8659-8668.
70. Girardini J.E., Napoli M., Piazza S., Rustighi A., Marotta C., Radaelli E., Capaci V., Jordan L., Quinlan P., Thompson A., Mano M., Rosato A., Crook T., Scanziani E., Means A.R., Lozano G., Schneider C. and Del Sal G. (2011). A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20, 79-91.
71. Glickman J.N., Yang A., Shahsafaei A., McKeon F. and Odze R.D. (2001). Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum. Pathol. 32, 1157-1165.
72. Gu X., Coates P.J., MacCallum S.F., Boldrup L., Sjostrom B. and Nylander K. (2007). TRAF4 is potently induced by TAp63 isoforms and localised according to differentiation in SCCHN. Cancer Biol. Ther. 6, 1986-1990.
73. Gualco G., Weiss L.M. and Bacchi C.E. (2008). Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum. Pathol. 39, 1505-1510.
74. Guan M. and Chen Y. (2005). Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J. Clin. Pathol. 58, 1175-1179.
75. Guan X., Zhang N., Yin Y., Kong B., Yang Q., Han Z. and Yang X. (2012). Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables. J. Exp. Clin. Cancer Res. 31, 89.
76. Guo H.Q., Huang G.L., Liu O.F., Liu Y.Y., Yao Z.H., Yao S.N., Zhao Y., Liu T., Pu X.X., Lin T.Y. and Yang S.J. (2012). p63 Expression is a prognostic factor in colorectal cancer. Int. J. Biol. Markers 27, e212-218.
77. Gutgemann A., Golob M., Muller S., Buettner R. and Bosserhoff A.K. (2001). Isolation of invasion-associated cDNAs in melanoma. Arch. Dermatol. Res. 293, 283-290.
78. Gutierrez M.I., Siraj A.K., Bhargava M., Ozbek U., Banavali S., Chaudhary M.A., El Solh H. and Bhatia K. (2003). Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia 17, 1845-1850.
79. Hagerstrand D., Tong A., Schumacher S.E., Ilic N., Shen R.R., Cheung H.W., Vazquez F., Shrestha Y., Kim S.Y., Giacomelli A.O., Rosenbluh J., Schinzel A.C., Spardy N.A., Barbie D.A., Mermel C.H., Weir B.A., Garraway L.A., Tamayo P., Mesirov J.P., Beroukhim R. and Hahn W.C. (2013). Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 3, 1044-1057.
80. Hastak K., Alli E. and Ford J.M. (2010). Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70, 7970-7980.
81. He M., Liu Y., Deng X., Qi S., Sun X., Liu G. and Zhao M. (2013). Downregulation of miR-200b-3p by low p73 contributes to the androgenindependence of prostate cancer cells. Prostate 73, 1048-1056.
82. Hedvat C.V., Teruya-Feldstein J., Puig P., Capodieci P., Dudas M., Pica N., Qin J., Cordon-Cardo C. and Di Como C.J. (2005). Expression of p63 in diffuse large B-cell lymphoma. Appl. Immunohistochem. Mol. Morphol. 13, 237-242.
83. Herranz M., Urioste M., Santos J., Martinez-Delgado J.B., Rivas C., Benitez J. and Fernandez-Piqueras J. (2000). Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia 14, 1325-1327.
84. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., Ratovitski E.A., Jen J. and Sidransky D. (2000). AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 97, 5462-5467.
85. Holcakova J., Ceskova P., Hrstka R., Muller P., Dubska L., Coates P.J., Palecek E. and Vojtesek B. (2008). The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis. Cell Mol. Biol. Lett. 13, 404-420.
86. Holembowski L., Schulz R., Talos F., Scheel A., Wolff S., Dobbelstein M. and Moll U. (2011). While p73 is essential, p63 is completely dispensable for the development of the central nervous system. Cell Cycle 10, 680-689.
87. Horvilleur E., Bauer M., Goldschneider D., Mergui X., de la Motte A., Benard J., Douc-Rasy S. and Cappellen D. (2008). p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res. 36, 4222-4232.
88. Humphrey P.A. (2007). Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J. Clin. Pathol. 60, 35-42.
89. Humphries L.A., Godbersen J.C., Danilova O.V., Kaur P., Christensen B.C. and Danilov A.V. (2013). Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. Br. J. Haematol. 163, 590-602.
90. Ibrahim N., He L., Leong C.O., Xing D., Karlan B.Y., Swisher E.M., Rueda B.R., Orsulic S. and Ellisen L.W. (2010). BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Res. 70, 7155-7165.
91. Imyanitov E.N., Birrell G.W., Filippovich I., Sorokina N., Arnold J., Mould M.A., Wright K., Walsh M., Mok S.C., Lavin M.F., Chenevix-Trench G. and Khanna K. K. (1999). Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 18, 4640-4642.
92. Ito Y., Takeda T., Wakasa K., Tsujimoto M., Sakon M. and Matsuura N. (2001). Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. Int. J. Mol. Med. 8, 67-71.
93. Jewell E.L., Darcy K.M., Hutson A., Lee P.S., Havrilesky L.J., Grace L.A., Berchuck A. and Secord A.A. (2009). Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 115, 424-429.
94. Kabos P., Haughian J.M., Wang X., Dye W.W., Finlayson C., Elias A., Horwitz K.B. and Sartorius C.A. (2011). Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res. Treat. 128, 45-55.
95. Kalebi A. and Hale M. (2008). p63 expression in ovarian tumours: immunopositivity in metastatic transitional cell carcinoma of the ovary. Histopathology 53, 228.
96. Kaneko Y., Sakurai S., Hironaka M., Sato S., Oguni S., Sakuma Y., Sato K., Sugano K. and Saito K. (2003). Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut 52, 641-646.
97. Karni-Schmidt O., Castillo-Martin M., Shen T.H., Gladoun N., Domingo-Domenech J., Sanchez-Carbayo M., Li Y., Lowe S., Prives C. and Cordon-Cardo C. (2011). Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am. J. Pathol. 178, 1350-1360.
98. Kawano S., Miller C.W., Gombart A.F., Bartram C.R., Matsuo Y., Asou H., Sakashita A., Said J., Tatsumi E. and Koeffler H.P. (1999). Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94, 1113-1120.
99. Koga F., Kawakami S., Fujii Y., Saito K., Ohtsuka Y., Iwai A., Ando N., Takizawa T., Kageyama Y. and Kihara K. (2003). Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res. 9, 5501-5507.
100. Kondo T., Oka T., Sato H., Shinnou Y., Washio K., Takano M., Morito T., Takata K., Ohara N., Ouchida M., Shimizu K. and Yoshino T. (2009). Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int. J. Oncol. 35, 547-557.
101. Konishi N., Nakamura M., Kishi M., Nishimine M., Ishida E. and Shimada K. (2002). Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am. J. Pathol. 160, 1207-1214.
102. Koster M.I. (2010). p63 in skin development and ectodermal dysplasias. J. Invest. Dermatol. 130, 2352-2358.
103. Kuo L.T., Kuo K.T., Lee M.J., Wei C.C., Scaravilli F., Tsai J.C., Tseng H.M., Kuo M.F. and Tu Y.K. (2009). Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int. J. Cancer 124, 2872-2879.
104. Lau L.M., Wolter J.K., Lau J.T., Cheng L.S., Smith K.M., Hansford L.M., Zhang L., Baruchel S., Robinson F. and Irwin M. S. (2009). Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28, 2024-2033.
105. Lee A.H. (2013). Use of immunohistochemistry in the diagnosis of problematic breast lesions. J. Clin. Pathol. 66, 471-477.
106. Leong C.O., Vidnovic N., DeYoung M.P., Sgroi D. and Ellisen L.W. (2007). The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. Invest. 117, 1370-1380.
107. Leung T. H., Wong S. C., Chan K. K., Chan D. W., Cheung A. N. and Ngan H. Y. (2013). The interaction between C35 and DeltaNp73 promotes chemo-resistance in ovarian cancer cells. Br. J. Cancer 109, 965-975.
108. Leupin N., Luthi A., Novak U., Grob T.J., Hugli B., Graber H., Fey M.F. and Tobler A. (2004). P73 status in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 45, 1205-1207.
109. Levine A.J. and Oren M. (2009). The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758.
110. Lewis T.S., McCormick R.S., Stone I.J., Emmerton K., Mbow B., Miyamoto J., Drachman J.G., Grewal I.S. and Law C.L. (2011). Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 25, 1007-1016.
111. Li H., Yao L., Ouyang T., Li J., Wang T., Fan Z., Fan T., Dong B., Lin B. and Xie Y. (2007). Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 28, 372-377.
112. Liao X.Y., Xue W.C., Shen D.H., Ngan H.Y., Siu M.K. and Cheung A.N. (2007). p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Histopathology 51, 477-483.
113. Lin D.C., Hao J.J., Nagata Y., Xu L., Shang L., Meng X., Sato Y., Okuno Y., Varela A.M., Ding L.W., Garg M., Liu L.Z., Yang H., Yin D., Shi Z.Z., Jiang Y.Y., Gu W.Y., Gong T., Zhang Y., Xu X., Kalid O., Shacham S., Ogawa S., Wang M.R. and Koeffler H.P. (2014). Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46, 467-473.
114. Liu S.S., Leung R.C., Chan K.Y., Chiu P.M., Cheung A.N., Tam K.F., Ng T.Y., Wong L.C. and Ngan H.Y. (2004). p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin. Cancer Res. 10, 3309-3316.
115. Lo Muzio L., Santarelli A., Caltabiano R., Rubini C., Pieramici T., Trevisiol L., Carinci F., Leonardi R., De Lillo A., Lanzafame S., Bufo P. and Piattelli A. (2005). p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum. Pathol. 36, 187-194.
116. Logotheti S., Pavlopoulou A., Galtsidis S., Vojtesek B. and Zoumpourlis V. (2013). Functions, divergence and clinical value of TAp73 isoforms in cancer. Cancer Metastasis Rev. 32, 511-534.
117. Loiseau H., Arsaut J. and Demotes-Mainard J. (1999). p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. Neurosci. Lett. 263, 173-176.
118. Loljung L., Coates P.J., Nekulova M., Laurell G., Wahlgren M., Wilms T., Widlof M., Hansel A. and Nylander K. (2014). High expression of p63 is correlated to poor prognosis in squamous cell carcinoma of the tongue. J. Oral Pathol. Med. 43, 14-19.
119. Lotan T.L., Ye H., Melamed J., Wu X.R., Shih Ie M. and Epstein J.I. (2009). Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am. J. Surg. Pathol. 33, 1037-1041.
120. Lu H., Yang X., Duggal P., Allen C.T., Yan B., Cohen J., Nottingham L., Romano R.A., Sinha S., King K.E., Weinberg W.C., Chen Z. and Van Waes C. (2011). TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res. 71, 6867-6877.
121. Marabese M., Marchini S., Marrazzo E., Mariani P., Cattaneo D., Fossati R., Compagnoni A., Signorelli M., Moll U.M., Codegoni A.M. and Broggini M. (2008). Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur. J. Cancer 44, 131-141.
122. Marchini S., Marabese M., Marrazzo E., Mariani P., Cattaneo D., Fossati R., Compagnoni A., Fruscio R., Lissoni A.A. and Broggini M. (2008). DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 19, 501-507.
123. Marzese D.M., Hoon D.S., Chong K.K., Gago F.E., Orozco J.I., Tello O.M., Vargas-Roig L.M. and Roque M. (2012). DNA methylation index and methylation profile of invasive ductal breast tumors. J. Mol. Diagn. 14, 613-622.
124. Massion P.P., Taflan P.M., Jamshedur Rahman S.M., Yildiz P., Shyr Y., Edgerton M.E., Westfall M.D., Roberts J.R., Pietenpol J.A., Carbone D.P. and Gonzalez A.L. (2003). Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 63, 7113-7121.
125. Matin R.N., Chikh A., Chong S.L., Mesher D., Graf M., Sanza P., Senatore V., Scatolini M., Moretti F., Leigh I.M., Proby C.M., Costanzo A., Chiorino G., Cerio R., Harwood C.A. and Bergamaschi D. (2013). p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J. Exp. Med. 210, 581-603.
126. Meier M., den Boer M.L., Meijerink J.P., Broekhuis M.J., Passier M.M., van Wering E.R., Janka-Schaub G.E. and Pieters R. (2006). Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 20, 1377-1384.
127. Melino G., De Laurenzi V. and Vousden K.H. (2002). p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer 2, 605-615.
128. Miller K., Price J.H., Dobbs S.P., McClelland R.H., Kennedy K. and McCluggage W.G. (2008). An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J. Clin. Pathol. 61, 652-657.
129. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R. and Bradley A. (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708-713.
130. Montagner M., Enzo E., Forcato M., Zanconato F., Parenti A., Rampazzo E., Basso G., Leo G., Rosato A., Bicciato S., Cordenonsi M. and Piccolo S. (2012). SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487, 380-384.
131. Morin R.D., Mungall K., Pleasance E., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S., Steidl C., Holt R., Birol I., Moore R., Connors J.M., Gascoyne R.D. and Marra M.A. (2013). Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122, 1256-1265.
132. Muller M., Schilling T., Sayan A.E., Kairat A., Lorenz K., Schulze-Bergkamen H., Oren M., Koch A., Tannapfel A., Stremmel W., Melino G. and Krammer P.H. (2005). TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12, 1564-1577.
133. Nekulova M., Zitterbart K., Sterba J. and Veselska R. (2010). Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and Np73 in medulloblastoma cell lines. J. Mol. Histol. 41, 267-275.
134. Nekulova M., Holcakova J., Coates P. and Vojtesek B. (2011). The role of p63 in cancer, stem cells and cancer stem cells. Cell. Mol. Biol. Lett. 16, 296-327.
135. Nekulova M., Holcakova J., Nenutil R., Stratmann R., Bouchalova P., Muller P., Moukova L., Coates P.J. and Vojtesek B. (2013). Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch. 463, 415-425.
136. Nenutil R., Ceskova P., Coates P.J., Nylander K. and Vojtesek B. (2003). Differential expression of p73alpha in normal ectocervical epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma. Int. J. Gynecol Pathol. 22, 386-392.
137. Ng S.W., Yiu G.K., Liu Y., Huang L.W., Palnati M., Jun S.H., Berkowitz R.S. and Mok S.C. (2000). Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 19, 1885-1890.
138. Novak U., Grob T.J., Baskaynak G., Peters U.R., Aebi S., Zwahlen D., Tschan M.P., Kreuzer K.A., Leibundgut E.O., Cajot J.F., Tobler A. and Fey M.F. (2001). Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann. Oncol. 12, 981-986.
139. Nylander K., Coates P.J. and Hall P.A. (2000). Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int. J. Cancer 87, 368-372.
140. Nylander K., Vojtesek B., Nenutil R., Lindgren B., Roos G., Zhanxiang W., Sjostrom B., Dahlqvist A. and Coates P. J. (2002). Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 198, 417-427.
141. Ojesina A.I., Lichtenstein L., Freeman S.S., Pedamallu C.S., Imaz-Rosshandler I., Pugh T.J., Cherniack A.D., Ambrogio L., Cibulskis K., Bertelsen B., Romero-Cordoba S., Trevino V., Vazquez-Santillan K., Guadarrama A.S., Wright A.A., Rosenberg M.W., Duke F., Kaplan B., Wang R., Nickerson E., Walline H.M., Lawrence M.S., Stewart C., Carter S.L., McKenna A., Rodriguez-Sanchez I.P., Espinosa-Castilla M., Woie K., Bjorge L., Wik E., Halle M.K., Hoivik E.A., Krakstad C., Gabino N.B., Gomez-Macias G.S., Valdez-Chapa L.D., Garza-Rodriguez M.L., Maytorena G., Vazquez J., Rodea C., Cravioto A., Cortes M.L., Greulich H., Crum C.P., Neuberg D.S., Hidalgo-Miranda A., Escareno C.R., Akslen L.A., Carey T.E., Vintermyr O.K., Gabriel S.B., Barrera-Saldana H.A., Melendez-Zajgla J., Getz G., Salvesen H.B. and Meyerson M. (2014). Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375.
142. Okada T., Nakamura M., Nishikawa J., Sakai K., Zhang Y., Saito M., Morishige A., Oga A., Sasaki K., Suehiro Y., Hinoda Y. and Sakaida I. (2013). Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas. Cancer Sci. 104, 1309-1314.
143. Owens S.R. and Greenson J.K. (2007). Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am. J. Surg. Pathol. 31, 285-290.
144. Palani M., Devan S., Arunkumar R. and Vanisree A.J. (2011). Frequency variations in the methylated pattern of p73/p21 genes and chromosomal aberrations correlating with different grades of glioma among south Indian population. Med. Oncol. 28 (Suppl 1), S445-452.
145. Park C.K. and Oh Y.H. (2005). Expression of p63 in reactive hyperplasias and malignant lymphomas. J. Korean Med. Sci. 20, 752-758.
146. Parrilla Castellar E.R., Jaffe E.S., Said J.W., Swerdlow S.H., Ketterling R.P., Knudson R.A., Sidhu J.S., Hsi E.D., Karikehalli S., Jiang L., Vasmatzis G., Gibson S.E., Ondrejka S., Nicolae A., Grogg K.L., Allmer C., Ristow K.M., Wilson W.H., Macon W.R., Law M.E., Cerhan J.R., Habermann T.M., Ansell S.M., Dogan A., Maurer M.J. and Feldman A.L. (2014). ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124, 1473-1480.
147. Pignon J.C., Grisanzio C., Geng Y., Song J., Shivdasani R.A. and Signoretti S. (2013). p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc. Natl. Acad. Sci. USA 110, 8105-8110.
148. Poli Neto O.B., Candido Dos Reis F.J., Zambelli Ramalho L.N., Nogueira A.A. and de Andrade J.M. (2006). p63 expression in epithelial ovarian tumors. Int. J. Gynecol. Cancer 16, 152-155.
149. Pruneri G., Fabris S., Dell'Orto P., Biasi M.O., Valentini S., Del Curto B., Laszlo D., Cattaneo L., Fasani R., Rossini L., Manzotti M., Bertolini F., Martinelli G., Neri A. and Viale G. (2005). The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J. Pathol. 206, 337-345.
150. Puig P., Capodieci P., Drobnjak M., Verbel D., Prives C., Cordon-Cardo C. and Di Como C.J. (2003). p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin. Cancer Res. 9, 5642-5651.
151. Ramalho F.S., Ramalho L.N., Della Porta L. and Zucoloto S. (2006). Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21, 1276-1280.
152. Redon R., Muller D., Caulee K., Wanherdrick K., Abecassis J. and du Manoir S. (2001). A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 61, 4122-4129.
153. Redon R., Hussenet T., Bour G., Caulee K., Jost B., Muller D., Abecassis J. and du Manoir S. (2002). Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res. 62, 6211-6217.
154. Reis-Filho J.S., Simpson P.T., Fulford L.G., Martins A. and Schmitt F.C. (2003a). P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol. Res. Pract. 199, 785-793.
155. Reis-Filho J.S., Simpson P.T., Martins A., Preto A., Gartner F. and Schmitt F.C. (2003b). Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 443, 122-132.
156. Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T., Nesland J.M., Pereira E.M., Lakhani S.R. and Schmitt F.C. (2006). Metaplastic breast carcinomas are basal-like tumours. Histopathology 49, 10-21.
157. Reisenbichler E.S., Balmer N.N., Adams A.L., Pfeifer J.D. and Hameed O. (2011). Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction. Mod. Pathol. 24, 185-193.
158. Rinne T., Brunner H.G. and van Bokhoven H. (2007). p63-associated disorders. Cell Cycle 6, 262-268.
159. Rocco J.W., Leong C.O., Kuperwasser N., De Young M.P. and Ellisen L.W. (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9, 45-56.
160. Romano R.A., Smalley K., Magraw C., Serna V.A., Kurita T., Raghavan S. and Sinha S. (2012). DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development 139, 772-782.
161. Rosenbluth J.M., Johnson K., Tang L., Triplett T. and Pietenpol J.A. (2009). Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle 8, 3702-3706.
162. Rossi G., Pelosi G., Barbareschi M., Graziano P., Cavazza A. and Papotti M. (2013). Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int. J. Surg. Pathol. 21, 326-336.
163. Rufini A., Agostini M., Grespi F., Tomasini R., Sayan B.S., Niklison-Chirou M.V., Conforti F., Velletri T., Mastino A., Mak T.W., Melino G. and Knight R.A. (2011). p73 in Cancer. Genes Cancer 2, 491-502.
164. Sahu G.R. and Das B.R. (2005). Alteration of p73 in pediatric de novo acute lymphoblastic leukemia. Biochem. Biophys Res. Commun. 327, 750-755.
165. Sailer V., Stephan C., Wernert N., Perner S., Jung K., Dietel M. and Kristiansen G. (2013). Comparison of p40 (DeltaNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells? Histopathology 63, 50-56.
166. Sang M., Li Y., Ozaki T., Ono S., Ando K., Yamamoto H., Koda T., Geng C. and Nakagawara A. (2006). p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers. Biochem. Biophys. Res. Commun. 347, 327-333.
167. Schittek B., Sauer B. and Garbe C. (1999). Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines. Int. J. Cancer 82, 583-586.
168. Schuster A., Schilling T., De Laurenzi V., Koch A.F., Seitz S., Staib F., Teufel A., Thorgeirsson S.S., Galle P., Melino G., Stremmel W., Krammer P.H. and Muller M. (2010). DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 9, 2629-2639.
169. Schwartz D.I., Lindor N.M., Walsh-Vockley C., Roche P.C., Mai M., Smith D., Liu W. and Couch F.J. (1999). p73 mutations are not detected in sporadic and hereditary breast cancer. Breast Cancer Res. Treat. 58, 25-29.
170. Scott D.W., Mungall K.L., Ben-Neriah S., Rogic S., Morin R.D., Slack G.W., Tan K.L., Chan F.C., Lim R.S., Connors J.M., Marra M.A., Mungall A.J., Steidl C. and Gascoyne R.D. (2012). TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 119, 4949-4952.
171. Sen T., Sen N., Brait M., Begum S., Chatterjee A., Hoque M. O., Ratovitski E. and Sidransky D. (2011). DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res. 71, 1167-1176.
172. Shen L., Kim S.H. and Chen C.Y. (2012). Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. PLoS One 7, e40435.
173. Shen L., Kondo Y., Ahmed S., Boumber Y., Konishi K., Guo Y., Chen X., Vilaythong J.N. and Issa J.P. (2007). Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 67, 11335-11343.
174. Signoretti S., Pires M.M., Lindauer M., Horner J.W., Grisanzio C., Dhar S., Majumder P., McKeon F., Kantoff P.W., Sellers W.R. and Loda M. (2005). p63 regulates commitment to the prostate cell lineage. Proc. Natl. Acad. Sci. USA 102, 11355-11360.
175. Signoretti S., Waltregny D., Dilks J., Isaac B., Lin D., Garraway L., Yang A., Montironi R., McKeon F. and Loda M. (2000). p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 157, 1769-1775.
176. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Juul N., Leong C.O., Calogrias D., Buraimoh A., Fatima A., Gelman R.S., Ryan P.D., Tung N.M., De Nicolo A., Ganesan S., Miron A., Colin C., Sgroi D.C., Ellisen L.W., Winer E.P. and Garber J.E. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145-1153.
177. Simoes-Wust A.P., Sigrist B., Belyanskaya L., Hopkins Donaldson S., Stahel R.A. and Zangemeister-Wittke U. (2005). DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J. Neurooncol. 72, 29-34.
178. Siu L.L., Chan J.K., Wong K.F. and Kwong Y.L. (2002). Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am. J. Pathol. 160, 59-66.
179. Soldevilla B., Diaz R., Silva J., Campos-Martin Y., Munoz C., Garcia V., Garcia J.M., Pena C., Herrera M., Rodriguez M., Gomez I., Mohamed N., Marques M.M., Bonilla F. and Dominguez G. (2011). Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients. Clin. Cancer Res. 17, 6029-6039.
180. Song Y., Li L., Ou Y., Gao Z., Li E., Li X., Zhang W., Wang J., Xu L., Zhou Y., Ma X., Liu L., Zhao Z., Huang X., Fan J., Dong L., Chen G., Ma L., Yang J., Chen L., He M., Li M., Zhuang X., Huang K., Qiu K., Yin G., Guo G., Feng Q., Chen P., Wu Z., Wu J., Ma L., Zhao J., Luo L., Fu M., Xu B., Chen B., Li Y., Tong T., Wang M., Liu Z., Lin D., Zhang X., Yang H., Wang J. and Zhan Q. (2014). Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91-95.
181. Srinivasan M. and Parwani A.V. (2011). Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma. Diagn. Pathol. 6, 67.
182. Steder M., Alla V., Meier C., Spitschak A., Pahnke J., Furst K., Kowtharapu B.S., Engelmann D., Petigk J., Egberts F., Schad-Trcka S.G., Gross G., Nettelbeck D.M., Niemetz A. and Putzer B.M. (2013). DNp73 exerts function in metastasis initiation by disconnecting the inhibitory role of EPLIN on IGF1R-AKT/STAT3 signaling. Cancer Cell 24, 512-527.
183. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., Shefler E., Ramos A.H., Stojanov P., Carter S.L., Voet D., Cortes M.L., Auclair D., Berger M.F., Saksena G., Guiducci C., Onofrio R.C., Parkin M., Romkes M., Weissfeld J.L., Seethala R.R., Wang L., Rangel-Escareno C., Fernandez-Lopez J.C., Hidalgo-Miranda A., Melendez-Zajgla J., Winckler W., Ardlie K., Gabriel S.B., Meyerson M., Lander E.S., Getz G., Golub T.R., Garraway L A. and Grandis J.R. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160.
184. Su X., Chakravarti D. and Flores E.R. (2013). p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat. Rev. Cancer 13, 136-143.
185. Tacha D., Bremer R., Haas T. and Qi W. (2014). An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers. Arch. Pathol. Lab. Med. 138, 1358-1364.
186. Takahashi H., Fukutome K., Watanabe M., Furusato M., Shiraishi T., Ito H., Suzuki H., Ikawa S. and Hano H. (2001). Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma. Prostate 47, 85-90.
187. Talos F., Abraham A., Vaseva A.V., Holembowski L., Tsirka S.E., Scheel A., Bode D., Dobbelstein M., Bruck W. and Moll U.M. (2010). p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ. 17, 1816-1829.
188. Thurfjell N., Coates P.J., Uusitalo T., Mahani D., Dabelsteen E., Dahlqvist A., Sjostrom B., Roos G. and Nylander K. (2004). Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int. J. Oncol. 25, 27-35.
189. Thurfjell N., Coates P.J., Vojtesek B., Benham-Motlagh P., Eisold M. and Nylander K. (2005). Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int. J. Mol. Med. 16, 1065-1070.
190. Tiwary R., Yu W., Sanders B.G. and Kline K. (2011). alpha-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res. 13, R1.
191. Tomasini R., Tsuchihara K., Wilhelm M., Fujitani M., Rufini A., Cheung C.C., Khan F., Itie-Youten A., Wakeham A., Tsao M.S., Iovanna J.L., Squire J., Jurisica I., Kaplan D., Melino G., Jurisicova A. and Mak T.W. (2008). TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677-2691.
192. Tomkova K., Belkhiri A., El-Rifai W. and Zaika A. I. (2004). p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res. 64, 6390-6393.
193. Trinh X.B., Tjalma W.A., Dirix L.Y., Vermeulen P.B., Peeters D.J., Bachvarov D., Plante M., Berns E.M., Helleman J., Van Laere S.J. and van Dam P.A. (2011). Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One 6, e22469.
194. Tsao H., Zhang X., Majewski P. and Haluska F.G. (1999). Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res. 59, 172-174.
195. Tucci P., Agostini M., Grespi F., Markert E.K., Terrinoni A., Vousden K.H., Muller P.A., Dotsch V., Kehrloesser S., Sayan B.S., Giaccone G., Lowe S.W., Takahashi N., Vandenabeele P., Knight R.A., Levine A.J. and Melino G. (2012). Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 109, 15312-15317.
196. Tuve S., Wagner S.N., Schittek B. and Putzer B.M. (2004). Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int. J. Cancer 108, 162-166.
197. Urist M.J., Di Como C.J., Lu M.L., Charytonowicz E., Verbel D., Crum C.P., Ince T.A., McKeon F.D. and Cordon-Cardo C. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 1199-1206.
198. Ushiku T., Chong J.M., Uozaki H., Hino R., Chang M.S., Sudo M., Rani B.R., Sakuma K., Nagai H. and Fukayama M. (2007). p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Int. J. Cancer 120, 60-66.
199. van Doorn R., Zoutman W.H., Dijkman R., de Menezes R.X., Commandeur S., Mulder A.A., van der Velden P.A., Vermeer M.H., Willemze R., Yan P.S., Huang T.H. and Tensen C.P. (2005). Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.J. Clin. Oncol. 23, 3886-3896.
200. Vasmatzis G., Johnson S.H., Knudson R.A., Ketterling R.P., Braggio E., Fonseca R., Viswanatha D.S., Law M.E., Kip N.S., Ozsan N., Grebe S.K., Frederick L.A., Eckloff B.W., Thompson E.A., Kadin M.E., Milosevic D., Porcher J.C., Asmann Y.W., Smith D.I., Kovtun I.V., Ansell S.M., Dogan A. and Feldman A.L. (2012). Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 120, 2280-2289.
201. Vayssade M., Haddada H., Faridoni-Laurens L., Tourpin S., Valent A., Benard J. and Ahomadegbe J.C. (2005). P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int. J. Cancer 116, 860-869.
202. Velletri T., Romeo F., Tucci P., Peschiaroli A., Annicchiarico-Petruzzelli M., Niklison-Chirou M.V., Amelio I., Knight R.A., Mak T.W., Melino G. and Agostini M. (2013). GLS2 is transcriptionally regulated by p73 and contributes to neuronal differentiation. Cell Cycle 12, 3564-3573.
203. Veselska R., Neradil J., Nekulova M., Dobrucka L., Vojtesek B., Sterba J. and Zitterbart K. (2013). Intracellular distribution of the DeltaNp73 protein isoform in medulloblastoma cells: a study with newly generated rabbit polyclonal antibodies. Histol. Histopathol. 28, 913-924.
204. Vilgelm A.E., Hong S.M., Washington M.K., Wei J., Chen H., El-Rifai W. and Zaika A. (2010). Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. Oncogene 29, 5861-5868.
205. Vogt A.P., Cohen C. and Siddiqui M.T. (2014). p40 (DeltaNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis. Diagn. Cytopathol. 42, 453-458.
206. Wang T.Y., Chen B.F., Yang Y.C., Chen H., Wang Y., Cviko A., Quade B.J., Sun D., Yang A., McKeon F.D. and Crum C.P. (2001). Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum. Pathol. 32, 479-486.
207. Wang Y., Kringen P., Kristensen G.B., Holm R., Baekelandt M.M., Olivier M., Skomedal H., Hainaut P., Trope C.G., Abeler V.M., Nesland J.M., Borresen-Dale A.L. and Helland A. (2004). Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum. Mutat. 24, 21-34.
208. Wang H., Liu Z., Li J., Zhao X., Wang Z. and Xu H. (2012a). DeltaNp63alpha mediates proliferation and apoptosis in human gastric cancer cells by the regulation of GATA-6. Neoplasma 59, 416-423.
209. Wang L., Gao R. and Yu L. (2012b). Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol. Biol. Rep. 39, 1731-1738.
210. Wang Y., Radhakrishnan D., He X., Peehl D.M. and Eng C. (2013). Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation. J. Clin. Endocrinol. Metab. 98, E586-594.
211. Wei J., O'Brien D., Vilgelm A., Piazuelo M.B., Correa P., Washington M.K., El-Rifai W., Peek R.M. and Zaika A. (2008). Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology 134, 1412-1423.
212. Wong S.W., Tiong K.H., Kong W.Y., Yue Y.C., Chua C.H., Lim J.Y., Lee C.Y., Quah S.I., Fow C., Chung C., So I., Tan B.S., Choo H.L., Rosli R., Cheong S.K. and Leong C.O. (2011). Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through upregulation of p73. Breast Cancer Res. Treat. 128, 301-313.
213. Xin L. (2013). Cells of origin for cancer: an updated view from prostate cancer. Oncogene 32, 3655-3663.
214. Yallowitz A.R., Alexandrova E.M., Talos F., Xu S., Marchenko N.D. and Moll U.M. (2014). p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. Cell Death Differ. 21, 645-654.
215. Yamaguchi K., Wu L., Caballero O.L., Hibi K., Trink B., Resto V., Cairns P., Okami K., Koch W.M., Sidransky D. and Jen J. (2000). Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int. J. Cancer 86, 684-689.
216. Yamaguchi H., Inokuchi K., Sakuma Y. and Dan K. (2001). Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 15, 1729-1734.
217. Yamaki T., Suenaga Y., Iuchi T., Alagu J., Takatori A., Itami M., Araki A., Ohira M., Inoue M., Kageyama H., Yokoi S., Saeki N. and Nakagawara A. (2013). Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. Sci. Rep. 3, 1160.
218. Yamamoto T., Oda K., Miyazaki K., Ichigotani Y., Takenouchi Y., Kamei T., Shirafuji N., Nimura Y., Hamaguchi M. and Matsuda S. (2001). p73 is highly expressed in myoepithelial cells and in carcinomas with metaplasia. Int. J. Oncol. 19, 271-276.
219. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D. and McKeon F. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, deathinducing, and dominant-negative activities. Mol. Cell 2, 305-316.
220. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C. and McKeon F. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714-718.
221. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F. and Caput D. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99-103.
222. Ye B., Wang X., Yang Z., Sun Z., Zhang R., Hu Y., Lu Y. and Du J. (2012). p53 and p73 expression in esophageal carcinoma correlate with clinicopathology of tumors. Hepatogastroenterology 59, 2192-2195.
223. Yokomizo A., Mai M., Bostwick D.G., Tindall D.J., Qian J., Cheng L., Jenkins R.B., Smith D.I. and Liu W. (1999a). Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39, 94-100.
224. Yokomizo A., Mai M., Tindall D.J., Cheng L., Bostwick D.G., Naito S., Smith D.I. and Liu W. (1999b). Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 18, 1629-1633.
225. Zaika A.I., Kovalev S., Marchenko N.D. and Moll U.M. (1999). Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59, 3257-3263.
226. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E. and Moll U.M. (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196, 765-780.
227. Zaika E., Bhardwaj V., Wei J., Washington M.K., Souza R., El-Rifai W. and Zaika A. (2013). Proinflammatory cytokines and bile acids upregulate DeltaNp73 protein, an inhibitor of p53 and p73 tumor suppressors. PLoS One 8, e64306.
228. Zangen R., Ratovitski E. and Sidransky D. (2005). DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4, 1313-1315.
229. Zhang H. and Rosdahl I. (2001). Expression of oncogenes, tumour suppressor, mismatch repair and apoptosis-related genes in primary and metastatic melanoma cells. Int. J. Oncol. 19, 1149-1153.
230. Zhang H., Schneider J. and Rosdahl I. (2002). Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. Int. J. Oncol. 21, 43-48.
231. Zhang X., Cao P., Zhai Y., Zhang H., Cui Y., Wu Z., Yuan X., Wang Z., Li P., Yu L., Xia X., He F. and Zhou G. (2014). Association between the p73 G4C14-to-A4T14 polymorphism and risk of nasopharyngeal carcinoma: a case-control and family-based study. Carcinogenesis 35, 1977-1982.
232. Zitterbart K., Zavrelova I., Kadlecova J., Spesna R., Kratochvilova A., Pavelka Z. and Sterba J. (2007). p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol. 114, 641-650.
233. Zucchi I., Astigiano S., Bertalot G., Sanzone S., Cocola C., Pelucchi P., Bertoli G., Stehling M., Barbieri O., Albertini A., Scholer H.R., Neel B.G., Reinbold R.A. and Dulbecco R. (2008). Distinct populations of tumor-initiating cells derived from a tumor generated by rat mammary cancer stem cells. Proc. Natl. Acad. Sci. USA 105, 16940-16945